Recent Research into the Equine Encephalitis - Pipeline Review, H2 2016

Equine Encephalitis - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Equine Encephalitis (Central Nervous System) pipeline landscape.

Equine encephalitis (EE) is mosquito transmitted disease that can cause severe inflammation of the brain (encephalitis) in humans. Symptoms include the sudden onset of fever, chills, body and joint aches. Infection can develop into severe encephalitis, resulting in headache, disorientation, tremors, seizures and paralysis. Permanent brain damage, coma and death may also occur in some cases. Approximately a third of patients who develop EE die, and many of those who survive have mild to severe brain damage.

Complete report available @ Equine Encephalitis - Pipeline Review, H2 2016

Report Highlights

This report provides comprehensive information on the therapeutics under development for Equine Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Equine Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 8 and 3 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 1 molecules, respectively for Equine Encephalitis.

Equine Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Equine Encephalitis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Equine Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Equine Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Equine Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Equine Encephalitis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Equine Encephalitis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Equine Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Akshaya Bio Inc. Altravax, Inc. EpiVax, Inc. Integrated BioTherapeutics, Inc. Karyopharm Therapeutics, Inc. Profectus BioSciences, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###